These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31511153)

  • 21. Add-on parenteral therapy in pulmonary arterial hypertension: The good, the bad, and the ugly.
    Schoenberg NC; Farber HW
    J Heart Lung Transplant; 2019 Sep; 38(9):1003-1005. PubMed ID: 31495406
    [No Abstract]   [Full Text] [Related]  

  • 22. Special delivery: Engineered endothelial cells for pulmonary arterial hypertension.
    Chambers DC
    Respirology; 2019 Nov; 24(11):1042-1043. PubMed ID: 31426124
    [No Abstract]   [Full Text] [Related]  

  • 23. Response.
    Klinger JR; Elliott G; Levine DJ; Bossone E; Duvall L; Fagan K; Frantsve-Hawley J; Kawut SM; Ryan JJ; Rosenzweig EB; Sederstrom N; Steen VD; Badesch DB
    Chest; 2019 Jul; 156(1):187-188. PubMed ID: 31279370
    [No Abstract]   [Full Text] [Related]  

  • 24. Pulmonary Arterial Hypertension: Too Complex for Physicians, Too Complex for ICD Diagnosis Codes.
    Callahan SJ; Papani R
    Chest; 2019 May; 155(5):1077. PubMed ID: 31060691
    [No Abstract]   [Full Text] [Related]  

  • 25. Against the Odds: Risk Stratification with Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension.
    Richter MJ; Tello K
    Am J Respir Crit Care Med; 2020 Feb; 201(4):403-405. PubMed ID: 31726011
    [No Abstract]   [Full Text] [Related]  

  • 26. EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition.
    Pullamsetti SS; de Jesus Perez VA
    Am J Respir Crit Care Med; 2019 Nov; 200(9):1188-1190. PubMed ID: 31419389
    [No Abstract]   [Full Text] [Related]  

  • 27. BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
    Chen L; Liu C; Lu W; Wang T
    Am J Respir Crit Care Med; 2020 May; 201(10):1313. PubMed ID: 32032498
    [No Abstract]   [Full Text] [Related]  

  • 28. Does Golden Ratio Reside in Pulmonary Circulation?
    Yetkin E; Çuğlan B; Turhan H; Ozturk S
    Chest; 2019 Sep; 156(3):629-630. PubMed ID: 31511152
    [No Abstract]   [Full Text] [Related]  

  • 29. A Novel Peptide for Immunomodulation in Pulmonary Arterial Hypertension.
    Grinnan D; Farkas L
    Am J Respir Crit Care Med; 2019 Jun; 199(12):1460-1461. PubMed ID: 30973752
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk of Pulmonary Arterial Hypertension During Qing-Dai Use for the Treatment of Ulcerative Colitis.
    Adachi S; Nakano Y; Kondo T
    Circ J; 2020 Jul; 84(8):1235-1236. PubMed ID: 32655110
    [No Abstract]   [Full Text] [Related]  

  • 31. Imaging risk in pulmonary arterial hypertension.
    Badagliacca R; Vizza CD
    Eur Respir J; 2020 Sep; 56(3):. PubMed ID: 32973075
    [No Abstract]   [Full Text] [Related]  

  • 32. Questions Regarding the Value of CCL21 as a Potential Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann-Vold et al.
    Zhou RP; Wei X; Ma GG; Zhu F; Chen FH; Hu W
    Arthritis Rheumatol; 2019 Apr; 71(4):653-654. PubMed ID: 30281217
    [No Abstract]   [Full Text] [Related]  

  • 33. Reply to Chen
    Provencher S; Boucherat O; Berger RMF; Goumans MJ; Bonnet S
    Am J Respir Crit Care Med; 2020 May; 201(10):1313-1314. PubMed ID: 32032495
    [No Abstract]   [Full Text] [Related]  

  • 34. IL-6 in pulmonary hypertension: why novel is not always best.
    Toshner M; Rothman A
    Eur Respir J; 2020 Apr; 55(4):. PubMed ID: 32300021
    [No Abstract]   [Full Text] [Related]  

  • 35. Insufficient Evidence to Consider CCL21 a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann-Vold et al.
    Xu WD; Su LC; Huang AF
    Arthritis Rheumatol; 2019 Apr; 71(4):654-655. PubMed ID: 30653848
    [No Abstract]   [Full Text] [Related]  

  • 36. Reply.
    Hoffmann-Vold AM; Didriksen H; Molberg Ø
    Arthritis Rheumatol; 2019 Apr; 71(4):655-656. PubMed ID: 30663863
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluating a strategy of PAH therapy pre-treatment in patients with atrial septal defects and pulmonary arterial hypertension to permit safe repair ("treat-and-repair").
    Constantine A; Dimopoulos K
    Int J Cardiol; 2019 Sep; 291():142-144. PubMed ID: 31155330
    [No Abstract]   [Full Text] [Related]  

  • 38. Response.
    Gillmeyer KR; Lee MM; Link AP; Klings ES; Rinne ST; Wiener RS
    Chest; 2019 May; 155(5):1077-1078. PubMed ID: 31060692
    [No Abstract]   [Full Text] [Related]  

  • 39. TBX4 syndrome: a systemic disease highlighted by pulmonary arterial hypertension in its most severe form.
    Austin ED; Elliott CG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32409426
    [No Abstract]   [Full Text] [Related]  

  • 40. Correspondence regarding "T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease": a single-centre case series.
    Jansen SMA; van den Heuvel L; Meijboom LJ; Alsters SIM; Vonk Noordegraaf A; Houweling A; Bogaard HJ
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32409423
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.